finnCap disclosed Cambridge Cognition Holdings (LON:COG), boosting its price target to 115.00GBX earlier today
- Updated: September 24, 2016
Reporting as potential upside of 0.54%, finnCap upped the price target of Cambridge Cognition Holdings (LON:COG) to 115.00GBX
Yesterday Cambridge Cognition Holdings (LON:COG) traded 0.00% even at 74.50GBX. The company’s 50-day moving average is 57.73GBX and its 200-day moving average is 45.45GBX. The last stock close price is up 66.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 50,185 shares of the stock were exchanged, up from an average trading volume of 37,332
See Chart Below
Cambridge Cognition Holdings has a 52 week low of 30.00GBX and a 52 week high of 105.00GBX The company’s market cap is currently 0 GBX.
In addition to finnCap reporting its target price, a total of 1 firm has issued a report on the stock. The consensus target price is 100.00GBX with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Cambridge Cognition Holdings (LON:COG)
Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.